Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Q1 2019 Earnings Presentation
18 slides from Novo Nordisk A/s Class B's earnings presentation, May 2019
Slide 1: Conference call First quarter of 2019
Slide 1 Conference call First quarter of 2019
Slide 2: Agenda
Conference call First quarter of 2019 Slide 2 Agenda Highlights and key events Sales update R&D update Financials and outlook
Slide 3: Forward-looking statements
Conference call First quarter of 2019 Slide 3 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation as well as the company’s statutory Annual Report 2018 and Form 20-F, which were both filed with the
Slide 4: Highlights – First quarter of 2019
Conference call First quarter of 2019 Slide 4 Highlights – First quarter of 2019 Sales update Sales increased by 9% and by 4% at CER to DKK 29.3 billion driven by • International Operations sales growth of 13% and of 13% at CER • North America Operations sales growth of 4% and decline of 4% at CER •
Slide 5: Total sales growth of 4% driven by IO with 13% sales growth partly offset by 4% sales decline in NAO
Conference call First quarter of 2019 Slide 5 Total sales growth of 4% driven by IO with 13% sales growth partly offset by 4% sales decline in NAO Reported sales split for first quarter of 2019 Growth drivers for first quarter of 2019 Insulin GLP-1 Other diabetes IO sales growth of 13% supported by
Slide 6: Total sales growth of 4% driven by diabetes and obesity sales growth of 5% and stable biopharm sales
Conference call First quarter of 2019 Slide 6 Total sales growth of 4% driven by diabetes and obesity sales growth of 5% and stable biopharm sales Added reported sales and growth per therapy area and operational units at CER Growth drivers for first quarter of 2019 International Operations North Ame
Slide 7: Global diabetes market leadership strengthened to 28.1%, partly driven by insulin volume market share
Conference call First quarter of 2019 Slide 7 Global diabetes market leadership strengthened to 28.1%, partly driven by insulin volume market share increase of 0.6%-point Expanded global diabetes value market Global insulin volume market share increased leadership by 0.6%-point to 28.1% 0.6%-point t
Slide 8: Ozempic® now launched in 19 countries and off to a solid start across markets
Conference call First quarter of 2019 Slide 8 Ozempic® now launched in 19 countries and off to a solid start across markets Ozempic® monthly volume market share uptake USA GLP-1 NBRx market share across Europe and Canada NN GLP-1 Victoza® Ozempic® dulaglutide Denmark Switzerland Ireland Netherlands
Slide 9: Ozempic® launch has stabilised Novo Nordisk's total US GLP-1 market share
Conference call First quarter of 2019 Slide 9 Ozempic® launch has stabilised Novo Nordisk’s total US GLP-1 market share in a market growing 29% annually USA GLP-1 quarterly prescription market development USA GLP-1 volume market share Annual market growth (RHS)1 exenatide ER NN GLP-1 dulaglutide Qua
Slide 10: Saxenda® sales growth of 51% in first quarter of 2019
Conference call First quarter of 2019 Slide 10 Saxenda® sales growth of 51% in first quarter of 2019 and market development activities continue globally Novo Nordisk has market leadership within the Saxenda® sales growth in both IO and NAO global obesity market DKK International Operations North Ame
Slide 11: Stable biopharm sales supported by commercial execution and global product launches
Conference call First quarter of 2019 Slide 11 Stable biopharm sales supported by commercial execution and global product launches Stable biopharm sales despite Biopharm sales supported by strong global NovoSeven® sales decline commercial execution Unchanged Biopharm sales driven by International Gr
Slide 12: Oral semaglutide filed in the USA, the EU and Canada, and Ozempic® CV risk reduction indication filed
Conference call First quarter of 2019 Slide 12 Oral semaglutide filed in the USA, the EU and Canada, and Ozempic® CV risk reduction indication filed in the USA Expected timelines for the FDA review Oral semaglutide filed in key markets Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Three FDA filings: • NDA
Slide 13: Key development milestones
Conference call First quarter of 2019 Slide 13 Key development milestones • Oral semaglutide filed with the US FDA for diabetes with six months review time and in the EU and Canada • Oral semaglutide and Ozempic® US FDA filed for CV risk reduction indications with ten months review time Diabetes • T
Slide 14: R&D milestones in 2019
Conference call First quarter of 2019 Slide 14 R&D milestones in 2019 Clinical milestones1 Regulatory milestones1 Project Q1 2019 Q2 2019 Q3 2019 Q4 2019 Phase 3b results Tresiba® (vs glargine U300) US submission FOCUS trial initiation FLOW trial initiation Ozempic® (CV label update) (Outcome
Slide 15: Financial results – First quarter of 2019
Conference call First quarter of 2019 Slide 15 Financial results – First quarter of 2019 First quarter First quarter Change Change In DKK million of 2019 of 2018 (reported) (CER) Sales 29,291 26,930 9% 4% Gross profit 24,559 22,733 8% Gross margin 83.8% 84.4% Sales and distribution costs 6,946 6,451
Slide 16: Financial outlook for 2019
Conference call First quarter of 2019 Slide 16 Financial outlook for 2019 Expectations Expectations 3 May 2019 1 Feb 2019 Sales growth – at CER 2% to 5% 2% to 5% Sales growth - reported Around 3%-points higher Around 2%-points higher Operating profit growth – at CER 2% to 6% 2% to 6% Operating profi
Slide 17: Key take-aways – First quarter of 2019
Conference call First quarter of 2019 Slide 17 Key take-aways – First quarter of 2019 Diabetes franchise grew 4% and Novo Nordisk retains world leader position with a market share of 28.1% (up from 27.5%) • Insulin sales increased 2% and Novo Nordisk has expanded its volume market leader position to
Slide 18: Investor contact information
Conference call First quarter of 2019 Slide 18 Investor contact information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the stock exchange in Novo Nordisk A/S Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on Investor Relations the New York Stock Ex